<?xml version="1.0" encoding="UTF-8"?>
<p id="Par46">Secondly, as currently-available LAIV is also produced in embryonated chicken eggs, it is plagued by many of the same concerns as egg-based IIV. In 2019 AstraZenecaâ€™s LAIV product FluMist experienced manufacturing issues due to low yields in two strains, resulting in a reduction in shipments worldwide [
 <xref ref-type="bibr" rid="CR35">35</xref>].
</p>
